MONTREAL, Sept. 10 /PRNewswire/ - Resonant Medical, the world leader in 3D ultrasound image-guided adaptive radiotherapy products, announced today that Mr. Joe Redfearn has joined the Company as Vice President Global Sales. This is a new position for Resonant Medical, and in this role, Mr. Redfearn will be responsible for the Company's global sales and customer support activities. He will also contribute to the expansion of the international distribution network.
"Mr. Redfearn brings to Resonant a track record of successful capital equipment sales and support management," said Steve Arless, Resonant's president & CEO. "His experience in the US and international marketplaces will help us achieve our bold goals for the coming years.
Mr. Redfearn joins the Company from Stereotaxis, where he was Vice-President of Capital Sales. He is a seasoned executive that has grown in the medical device industry for over 25 years, where he has worked for CryoCath Technologies, ThermoCardio Systems and CR Bard. "I'm excited to join the Resonant Medical Team and look forward to leading Resonant's efforts toward profitable revenue growth" commented Redfearn. "With new top management and proven product performance, Resonant is well-positioned for significant sales growth."
About Resonant Medical and Restitu(TM)
Resonant Medical Inc. is the world leader in 3D ultrasound image-guided radiotherapy products designed to improve treatment planning, verification and delivery. Recently, the company secured significant financing in order to develop and market Restitu(TM) add-on modules that will improve the quality of radiotherapy treatment for patients with breast, head & neck, cervix, bladder, and other soft tissue malignancies. These modules will compliment the previously released prostate module and Restitu(TM) platform, which are already in use in dozens of cancer clinics and university hospitals in North America.
The Restitu(TM) Platform accurately visualizes and corrects daily changes in tumor position, shape and size, thus ushering in a new era of 3D ultrasound (U/S) multimodality radiotherapy treatment planning and image guidance. Installed in CT-Sim rooms, Restitu U/S-Sim(TM) allows for better definition of planning tumor volumes with its patented IMPLICIT REGISTRATION(TM) technology that automatically fuses 3D U/S to CT data. With U/S-Sim, multimodality treatment planning has now been made possible and affordable for all clinics, with or without PET or MRI. Installed in treatment rooms, Restitu U/S-Guide(TM) allows for highly accurate patient position verification and alignment, with its proprietary MUTUAL REFERENCING(TM) technology that uses assisted segmentation for efficient and robust intramodality 3D U/S image-guidance.
Resonant Medical inc.CONTACT: Michele Jemus, Chief Financial Officer, Resonant Medical, (514)985-2442 x 270, F.: (514) 985-9662, mjemus@resonantmedical.com
